Closing

1D

YTD

Market cap

-

52 week high

-

52 week low

-

Volume

-

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

-

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

5

P/E

-

Operating Margin

-

Beta

-

Revenue Growth (Annual)

87.51%

52 week high

-

52 week low

-

Div. Yield

-

EPS Annual Growth

-

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Novan, Inc. is a medical dermatology company. The Company is focused on developing and commercializing therapeutic products for skin diseases. The Company is engaged in developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a focus on molluscum contagiosum (molluscum). The Company’s commercial portfolio includes six branded prescription drugs. It actively promotes three medical dermatological products in the United States, such as Wynzora (calcipotriene and betamethasone dipropionate), Rhofade (oxymetazoline hydrochloride), and Minolira (minocycline hydrochloride). Wynzora is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis. Rhofade is an alpha1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema. Minolira is indicated to treat inflammatory lesions.